This clinical trial is for men and women age 18 and older with Renal Cell Carcinoma to check safety and tolerability of PF-045118600 (an OX40 Antibody) in combination with Axitinib versus Axitinib in Immune-Checkpoint inhibitor exposed patients.
Renal cell carcinoma is a type of kidney cancer that affects mainly elderly population. Immunotherapy is a promising and fast expanding field of research and has proven its clinical potential in many types of cancers such as melanoma, bladder cancer, lung cancer and renal cell carcinoma.
Current treatments can be effective if disease is detected at early stage but usually disease is detected only when it is already advanced. Therefore, there is a need to find more effective treatments with fewer side effects.
OX40 Ab (PF-045118600) stimulates the immune system and may stop cancer cells from growing. There are clinical and nonclinical observations that OX40 Ab and Axitinib combined therapy may produce superior antitumor activity compared to one drug alone.
Study Arms: Arm 1 (Axitinib + OX40 Ab) and Arm 2 (Axitinib + placebo)